Hans Carl Hasselbalch

Summary

Affiliation: University of Copenhagen
Country: Denmark

Publications

  1. ncbi request reprint Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders
    M K Jensen
    Department of Haematology, Rigshospitalet, University Hospital of Copenhagen, Denmark
    Br J Haematol 110:116-24. 2000
  2. ncbi request reprint Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count
    M K Jensen
    Department of Haematology L, 4041, Rigshospitalet, University Hospital of Copenhagen, 2100 Copenhagen Ø, Denmark
    Eur J Haematol 66:143-51. 2001
  3. ncbi request reprint SU6668 in idiopathic myelofibrosis--a rational therapeutic approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesis
    H C Hasselbalch
    Department of Medicine, University of Copenhagen, Roskilde, Denmark
    Med Hypotheses 61:244-7. 2003
  4. doi request reprint Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera
    T S Larsen
    Department of Haematology, Odense University Hospital, Sdr Boulevard, 5000, Odense C, Denmark
    Ann Hematol 87:847-50. 2008
  5. doi request reprint Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?
    Hans Carl Hasselbalch
    Department of Hematology L, Herlev University Hospital, Denmark
    Leuk Res 33:11-8. 2009
  6. doi request reprint A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis?
    Hans C Hasselbalch
    Department of Hematology, Roskilde Hospital, University of Copenhagen, Denmark Electronic address
    Leuk Res 38:263-6. 2014
  7. doi request reprint The role of cytokines in the initiation and progression of myelofibrosis
    Hans C Hasselbalch
    Department of Hematology, Roskilde Hospital University of Copenhagen, Køgevej 7 13, 4000 Roskilde, Denmark
    Cytokine Growth Factor Rev 24:133-45. 2013
  8. doi request reprint Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?
    Hans Carl Hasselbalch
    Department of Hematology, Roskilde Hospital, University of Copenhagen, Køgevej 7 13, Roskilde, Denmark
    Leuk Res 37:214-20. 2013
  9. doi request reprint Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?
    Hans Carl Hasselbalch
    Department of Hematology, Roskilde Hospital, University of Copenhagen, Køgevej 7 13, Roskilde, Denmark
    Blood 119:3219-25. 2012
  10. doi request reprint High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis
    Hans Carl Hasselbalch
    Department of Hematology, Roskilde Hospital, University of Copenhagen, Roskilde, Denmark
    Leuk Res 35:1330-4. 2011

Collaborators

Detail Information

Publications58

  1. ncbi request reprint Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders
    M K Jensen
    Department of Haematology, Rigshospitalet, University Hospital of Copenhagen, Denmark
    Br J Haematol 110:116-24. 2000
    ..8% vs. 45%; P < 0.001) and increase of GPIIb/IIIa (49.1% vs. 95.7%; P < 0.001) and GPIV expression (17.8% vs. 55.2%; P < 0.001) was attenuated in patients...
  2. ncbi request reprint Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count
    M K Jensen
    Department of Haematology L, 4041, Rigshospitalet, University Hospital of Copenhagen, 2100 Copenhagen Ø, Denmark
    Eur J Haematol 66:143-51. 2001
    ..32 vs. 51.50%; p<0.01). These data document an increased frequency of PLA in non-stimulated whole blood in MPD associated with a previous history of thrombosis or microvascular disturbances...
  3. ncbi request reprint SU6668 in idiopathic myelofibrosis--a rational therapeutic approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesis
    H C Hasselbalch
    Department of Medicine, University of Copenhagen, Roskilde, Denmark
    Med Hypotheses 61:244-7. 2003
    ....
  4. doi request reprint Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera
    T S Larsen
    Department of Haematology, Odense University Hospital, Sdr Boulevard, 5000, Odense C, Denmark
    Ann Hematol 87:847-50. 2008
    ..0% in two patients with polycythemia vera treated with interferon alpha-2b (IFN-2b). Discontinuation of IFN-2b in one of the patients was followed by a sustained long-lasting (12 months of follow-up) major molecular response...
  5. doi request reprint Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?
    Hans Carl Hasselbalch
    Department of Hematology L, Herlev University Hospital, Denmark
    Leuk Res 33:11-8. 2009
    ....
  6. doi request reprint A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis?
    Hans C Hasselbalch
    Department of Hematology, Roskilde Hospital, University of Copenhagen, Denmark Electronic address
    Leuk Res 38:263-6. 2014
    ..Accordingly, this novel murine model may also have delivered the proof of concept of chronic inflammation as a trigger and driver of clonal evolution in MPNs...
  7. doi request reprint The role of cytokines in the initiation and progression of myelofibrosis
    Hans C Hasselbalch
    Department of Hematology, Roskilde Hospital University of Copenhagen, Køgevej 7 13, 4000 Roskilde, Denmark
    Cytokine Growth Factor Rev 24:133-45. 2013
    ....
  8. doi request reprint Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?
    Hans Carl Hasselbalch
    Department of Hematology, Roskilde Hospital, University of Copenhagen, Køgevej 7 13, Roskilde, Denmark
    Leuk Res 37:214-20. 2013
    ....
  9. doi request reprint Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?
    Hans Carl Hasselbalch
    Department of Hematology, Roskilde Hospital, University of Copenhagen, Køgevej 7 13, Roskilde, Denmark
    Blood 119:3219-25. 2012
    ....
  10. doi request reprint High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis
    Hans Carl Hasselbalch
    Department of Hematology, Roskilde Hospital, University of Copenhagen, Roskilde, Denmark
    Leuk Res 35:1330-4. 2011
    ..Alternatively, the highly elevated gene expression of CEACAM6 and 8 in PMF may be molecular markers of myelofibrotic transformation, implying enhanced proteolytic activity, egress of CD34+ cells into the circulation, and neoangiogenesis...
  11. doi request reprint A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms
    Hans Carl Hasselbalch
    Department of Hematology, Roskilde Hospital, University of Copenhagen, Denmark
    Expert Rev Hematol 4:637-55. 2011
    ....
  12. ncbi request reprint [Novel medical treatment modalities in hematology]
    Hans Carl Hasselbalch
    Herlev Hospital, haematologisk afdeling L, Herlev
    Ugeskr Laeger 170:2115-9. 2008
    ..Thalidomide, lenalidomide and bortezomib have all been shown to be highly effective in multiple myeloma, and JAK2-inhibitors have entered phase II studies of patients with JAK2-positive primary myelofibrosis and related diseases...
  13. ncbi request reprint Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?
    Hans Carl Hasselbalch
    Department of Haematology, Odense University Hospital, University of Southern Denmark, Odense, Denmark
    Leuk Res 30:1217-25. 2006
    ....
  14. doi request reprint Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms
    Vibe Skov
    Department of Clinical Genetics, Odense University Hospital, Denmark
    Leuk Lymphoma 53:123-9. 2012
    ....
  15. doi request reprint Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance
    Vibe Skov
    Department of Clinical Genetics, Odense University Hospital, Odense, Denmark
    Leuk Res 36:1387-92. 2012
    ..Our findings may reflect chronic inflammation to be of pathogenetic importance for the progression of these neoplasms toward the myelofibrotic end-stage and may also account for the increased frequency of second cancer in these diseases...
  16. doi request reprint Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission
    Thomas Stauffer Larsen
    Department of Hematology, Odense University Hospital, Denmark
    Hematology 14:331-4. 2009
    ..Finally, hematological remissions and major molecular responses can be sustained after discontinuation of long-term treatment with IFN2b...
  17. doi request reprint Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis
    Vibe Skov
    Department of Clinical Genetics, Odense University Hospital, Odense, Denmark
    Exp Hematol 40:771-780.e19. 2012
    ..Functional analysis suggests an important implication of these gene ontology clusters in the pathogenesis of these neoplasms and in disease evolution from ET over PV to PMF...
  18. doi request reprint Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis
    Vibe Skov
    Department of Clinical Genetics, Odense University Hospital, Odense, Denmark
    Eur J Haematol 87:54-60. 2011
    ..Finally, IFI27 may be a novel biomarker of disease activity and tumor burden in patients with CMPNs...
  19. doi request reprint High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden
    Thomas Stauffer Larsen
    Department of Haematology, Odense University Hospital, Denmark
    Hematology 13:71-6. 2008
    ..This study adds further support to the contention of the JAK2 V617F mutation as a marker of increased risk of thrombosis...
  20. doi request reprint Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden
    Thomas Stauffer Larsen
    Department of Hematology, Odense University Hospital, Odense, Denmark
    Hematology 14:11-5. 2009
    ..During a median follow-up of 24.2 months, no significant reductions in the JAK2 V617F allele burden were seen in patients treated with HU. We conclude that HU has only a limited effect on the JAK2 V617F allele burden in CMPD...
  21. doi request reprint Increase in circulating CD4⁺CD25⁺Foxp3⁺ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α
    Caroline Hasselbalch Riley
    Department of Hematology, Herlev Hospital, University of Copenhagen, Denmark
    Blood 118:2170-3. 2011
    ..2%) compared with healthy donors (6.1%; 95% CI 4.9% to 7.2%), patients with untreated chronic myeloproliferative neoplasms (6.9%; 95% CI 5.8% to 7.4%), or patients treated with hydroxyurea (5.8%; 95% CI 4.3% to 7.4%; P < .0001)...
  22. ncbi request reprint Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis
    Hans Carl Hasselbalch
    Department of Medicine, Division of Hematology and Oncology, Roskilde Hospital, Denmark
    Am J Hematol 74:238-42. 2003
    ..Combination therapy with HU or IFN seems safe and well tolerated and followed by a decrease in disease activity. A subgroup of patients in an early disease phase might benefit from imatinib therapy alone...
  23. doi request reprint Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha
    Thomas Stauffer Larsen
    Department of Hematology, Odense University Hospital, Denmark
    Leuk Res 37:1041-5. 2013
    ..Finally, long term treatment with rIFN-alpha2 was associated with a very low thrombosis rate. Our observations are supportive of the concept of early up-front treatment with rIFN-alpha2...
  24. ncbi request reprint The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders
    Thomas Stauffer Larsen
    Haematology, Odense University Hospital, Odense, Denmark
    Br J Haematol 136:745-51. 2007
    ..CMPDs. These results demonstrate the origin of the JAK2 V617F positive disorders in an early stem cell with both lymphoid and myeloid differentiation potential...
  25. ncbi request reprint Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia
    Thomas Stauffer Larsen
    Department of Haematology and Pathology, Odense University Hospital, Denmark
    APMIS 115:1267-73. 2007
    ..Accordingly, the WHO concept of two distinct entities, ET and prefibrotic IMF, does not seem to fit the model of JAK2-positive ET as part of a biological continuum of JAK2 V617F-positive chronic myeloproliferative disorders...
  26. ncbi request reprint Risk of Lymphoma and Solid Cancer among Patients with Rheumatoid Arthritis in a Primary Care Setting
    Christen Lykkegaard Andersen
    Department of Hematology, Roskilde University Hospital, Roskilde, Denmark The Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark
    PLoS ONE 9:e99388. 2014
    ..We investigated 1) the risk of lymphoproliferative malignancies and solid tumors in adults with RA identified in primary care and 2) the possible mediating role of blood eosinophilia in the clonal evolution of cancer in these patients...
  27. doi request reprint Transcriptional profiling of whole blood identifies a unique 5-gene signature for myelofibrosis and imminent myelofibrosis transformation
    Hans Carl Hasselbalch
    Department of Hematology, Roskilde Hospital, University of Copenhagen, Roskilde, Denmark
    PLoS ONE 9:e85567. 2014
    ..Accordingly, this gene-signature may reflect key processes in the pathogenesis and pathophysiology of myelofibrosis development. ..
  28. doi request reprint Eosinophilia in routine blood samples and the subsequent risk of hematological malignancies and death
    Christen Lykkegaard Andersen
    Department of Hematology, Roskilde University Hospital, Denmark The Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Denmark
    Am J Hematol 88:843-7. 2013
    ..Unexplained eosinophilia should prompt clinicians to consider conditions where early diagnosis may improve prognosis...
  29. ncbi request reprint Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives
    Hans Carl Hasselbalch
    Department of Hematology, Copenhagen University Hospital, Roskilde Hospital, Roskilde, Denmark
    Curr Drug Targets 12:392-419. 2011
    ....
  30. ncbi request reprint The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype
    Thomas Stauffer Larsen
    Department of Haematology, Odense University Hospital, Odense C, Denmark
    Eur J Haematol 79:508-15. 2007
    ..Together with physiological and genetic modifiers the phenotype may be determined by the JAK2 V617F allele burden. In the present study, we aimed to asses the JAK2 mutational load and its impact on phenotype...
  31. ncbi request reprint Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan
    Iben Nielsen
    Department of Hematology L, Rigshospitalet University Hospital, Copenhagen, Denmark
    Am J Hematol 74:26-31. 2003
    ..The incidence is markedly increased to about 30% when HU is preceded by treatment with BU. HU is not recommended for use in younger patients, in whom non-leukemogenic agents such as alpha-interferon and anagrelide should be used instead...
  32. doi request reprint The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis
    Malene Risum
    Department of Hematology, Roskilde Hospital, Denmark
    APMIS 119:498-504. 2011
    ..Although this difference was statistically significant, larger studies are needed to firmly support this conclusion...
  33. doi request reprint A novel immunohistochemical sequential multi-labelling and erasing technique enables epitope characterization of bone marrow pericytes in primary myelofibrosis
    Ann Madelung
    Department of Clinical Pathology, Hospital South Naestved, Ringstedgade 61, Naestved, Denmark
    Histopathology 60:554-60. 2012
    ..The aim of this study was to characterize bone marrow pericytes in primary myelofibrosis (PMF) using a novel multi-labelling immunohistochemical technique...
  34. ncbi request reprint Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera
    Morten Krogh Jensen
    Department of Haematology L, Righospilatet, University of Copenhagen, Denmark
    Eur J Haematol 69:43-9. 2002
    ..Increased plasma suPAR levels in patients with chronic myeloproliferative disorders may reflect increased uPAR production in the bone marrow, leading to enhanced bone marrow remodelling...
  35. ncbi request reprint The mevalonate pathway as a therapeutic target in the Ph-negative chronic myeloproliferative disorders
    Hans Carl Hasselbalch
    Department of Haematology, Odense University Hospital, University of Southern Denmark, Denmark
    Curr Drug Targets 8:247-56. 2007
    ....
  36. ncbi request reprint Systemic mastocytosis--a systematic review
    Christen Lykkegaard Andersen
    Department of Haematology, Roskilde Hospital, Denmark
    Dan Med J 59:A4397. 2012
    ..We here give a review of systemic mastocytosis in regards to cell biology, diagnostic approaches and clinical practice...
  37. ncbi request reprint [Eosinophilia--pathogenesis, classification and therapy]
    Christen Lykkegaard Andersen
    Rigshospitalet, Haematologisk Klinik, Vejle og Give Sygehuse, Haematologisk Afdeling, Herlev Hospital, Denmark
    Ugeskr Laeger 171:3256-62. 2009
    ..Unexplained eosinophilia should be managed in collaboration with a haematology department...
  38. ncbi request reprint Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders
    Morten Krogh Jensen
    Department of Haematology L, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark
    Eur J Haematol 71:377-84. 2003
    ..0004). These findings suggest that a disturbed TIMP-1/MMP ratio may reflect an imbalance of the extracellular homeostasis towards an increased matrix deposition promoting fibrosis...
  39. ncbi request reprint High prevalence of hyperhomocysteinemia due to marginal deficiency of cobalamin or folate in chronic myeloproliferative disorders
    M Faurschou
    Department of Hematology, Rigshospitalet, Copenhagen, Denmark
    Am J Hematol 65:136-40. 2000
    ..Vitamin therapy leads to normalization of P-HCY and should be considered, even though hyperhomocysteinemia does not seem to be of crucial importance for the thrombotic tendency in the myeloproliferative disorders...
  40. ncbi request reprint Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders
    Morten Krogh Jensen
    Department of Haematology, Rigshospitalet, University Hospital of Copenhagen, Denmark
    Am J Hematol 69:185-91. 2002
    ....
  41. ncbi request reprint A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis
    Thomas Stauffer Larsen
    Department of Hematology, Odense University Hospital, Sdr Boulevard, 5000 Odense C, Denmark
    Cancer Genet Cytogenet 172:107-12. 2007
    ..Cytogenetic analysis seems to identify a subgroup of patients with a distinct prognostic profile, and should be performed in conjunction with a JAK2 mutation analysis in patients suspected of a chronic myeloproliferative disease...
  42. doi request reprint Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia
    Sif Gudbrandsdottir
    Department of Hematology, Copenhagen University Hospital Roskilde, Roskilde, Denmark
    Blood 121:1976-81. 2013
    ..04). In conclusion, rituximab + dexamethasone induced higher response rates and longer time to relapse than dexamethasone alone. This study is registered at http://clinicaltrials.gov as NCT00909077...
  43. ncbi request reprint Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms
    Alexander Sidelmann Christensen
    Department of Hematology, Roskilde Hospital, University of Copenhagen, Roskilde, Denmark Electronic address
    Leuk Res 38:490-5. 2014
    ..The progression of kidney function and frequency of chronic kidney disease (CKD) in patients with the Philadelphia-negative myeloproliferative neoplasms (MPN) is unknown, although CKD is linked to increased mortality...
  44. ncbi request reprint Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat
    Christen Lykkegaard Andersen
    Department of Hematology, Roskilde University Hospital, Koegevej 7, 4000 Roskilde, Denmark Electronic address
    Leuk Res 38:816-21. 2014
    ..YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms. ..
  45. ncbi request reprint Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin
    Hans Carl Hasselbalch
    Department of Hematology L, Rigshospitalet, Copenhagen, Denmark
    Am J Hematol 70:92-9. 2002
    ..The highly positive results of the present study of transfusion-dependent patients with idiopathic myelofibrosis calls for further studies to delineate more precisely in larger series those patients who are likely to respond to rHuEpo...
  46. ncbi request reprint Anagrelide treatment in 52 patients with chronic myeloproliferative diseases
    E Penninga
    Department of Haematology, National University Hospital, Rigshospitalet, Copenhagen, Denmark
    Clin Lab Haematol 26:335-40. 2004
    ..Anagrelide is safe and effective in reducing the platelet counts, but a high proportion of the patients discontinue treatment because of the adverse effects of the drug...
  47. ncbi request reprint Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia
    M Faurschou
    Department of Haematology, The National University Hospital, Rigshospitalet, Copenhagen, Denmark
    Eur J Haematol 66:408-11. 2001
    ..Anti-CD20 antibody therapy seems to constitute a safe and efficient alternative to corticosteroids for the management of ITN patients with chronic thrombocytopenia...
  48. ncbi request reprint [New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene]
    Thomas Stauffer Larsen
    Odense Universitetshospital, Patologisk Institut og Haematologisk Afdeling X
    Ugeskr Laeger 168:3295-9. 2006
    ..The biological role of PRV-1 and the significance of alterations in PRV-1 gene expression levels during treatment remain to be clarified...
  49. ncbi request reprint [Rituximab. A monoclonal CD20 antibody--hematological indications and possible treatments for immunoinflammatory diseases]
    Per Boye Hansen
    Hillerød Sygehus, Medicinsk afdeling F
    Ugeskr Laeger 166:466-9. 2004
  50. ncbi request reprint [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation]
    Thomas Stauffer Larsen
    Odense Universitetshospital, Patologisk Institut og Haematologisk Afdeling X
    Ugeskr Laeger 168:3299-303. 2006
    ..The mutated JAK2 tyrosine kinase is an obvious potential target for a small-molecule inhibitor of tyrosine kinase activity...
  51. ncbi request reprint [STI571 (Glivec)--a new drug for the treatment of chronic myeloid leukemia]
    Hans Carl Hasselbalch
    Medicinsk afdeling, Amtssygehuset Roskilde, DK 4000 Roskilde
    Ugeskr Laeger 164:2914-7. 2002
    ..Perspectives for treatment with STI571 are described, as are combinations with alpha-interferon and other cytostatics with a synergistic profile...
  52. ncbi request reprint [The myelodysplastic syndrome I. Pathogenesis, clinical symptoms, diagnosis and differential diagnosis]
    Hans Carl Hasselbalch
    Medicinsk afdeling, Amtssygehuset Roskilde, DK 4000 Roskilde
    Ugeskr Laeger 164:476-9. 2002
    ....
  53. ncbi request reprint [The myelodysplastic syndrome II. New therapeutic principles, course and prognosis]
    Hans Carl Hasselbalch
    Medicinsk afdeling, Amtssygehuset Roskilde, DK 4000 Roskilde
    Ugeskr Laeger 164:479-82. 2002
    ..This system is able to distinguish between three distinct groups of patients with a highly different prognosis (low, intermediate, high risk), which is also of importance when evaluating the best treatment for the individual patient...
  54. ncbi request reprint B-cell depletion with rituximab-a targeted therapy for Graves' disease and autoimmune thyroiditis
    Hans Carl Hasselbalch
    Immunol Lett 88:85-6. 2003
  55. ncbi request reprint [Immunosuppressive treatment of the myelodysplastic syndrome]
    Mathilde Skaarup Larsen
    Medicinsk afdeling, Haematologisk Onkologisk Afsnit, Amtssygehuset Roskilde, Køgevej 7 13, DK 4000 Roskilde
    Ugeskr Laeger 165:2654-7. 2003
    ..Until recently the only possible treatment was supportive care with transfusions and antibiotics, but new options have now become available. In this article the results of immunosuppressive treatment are described and discussed...
  56. doi request reprint Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence
    Jean Jacques Lataillade
    Laboratoire de Recherche, Center de Transfusion Sanguine des Armeés CTSA, Hôpital Percy, Clamart, France
    Blood 112:3026-35. 2008
    ....
  57. ncbi request reprint [Tyrosine kinase inhibitors in the treatment of polycythemia vera and related conditions. Danish Society of Hematology]
    Thomas Stauffer Larsen
    Haematologisk Afdeling X, Odense Universitetshospital, DK 5000 Odense C
    Ugeskr Laeger 170:1031. 2008
  58. ncbi request reprint [Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia]
    Ole Weis Bjerrum
    Rigshospitalet, Finsenscentret, Haematologisk Klinik, København Ø
    Ugeskr Laeger 170:331-3. 2008
    ..A novel 2nd generation tyrosin kinase inhibitor--dasatinib (Sprycel)--is now available in cases of insufficient response or intolerance to imatinib...